We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Drug Candidate Reverses Arthritic Bone Loss in Models

By LabMedica International staff writers
Posted on 21 Feb 2018
A small molecule drug candidate was found to induce bone regeneration and reduce inflammation in various rat osteoarthritis models.

Human adult articular cartilage (AC) has little capacity for repair, and joint surface injuries often result in the development of osteoarthritis (OA), which is characterized by loss of bone matrix, hypertrophy, and chondrocyte apoptosis. More...
Inflammation mediated by interleukin (IL)-6 family cytokines has been identified as a critical driver of pro-arthritic changes in mouse and human joints, resulting in a feed-forward process driving expression of matrix degrading enzymes and IL-6 itself.

Investigators at the University of Southern California (Los Angeles, USA) sought potential drug candidates that would be able to reverse the inflammatory and degenerative effects of osteoarthritis while promoting regeneration and healing of bone and cartilage.

Towards this end, they used a high-throughput screening technique to identify a small molecule gp130 modulator from more than 170,000 candidate compounds. Gp130 is a transmembrane protein, which is the founding member of the class of all cytokine receptors. It forms one subunit of the type I cytokine receptor within the IL-6 receptor family. It is often referred to as the common gp130 subunit, and is important for signal transduction following cytokine engagement.

When tested on cultures of joint cartilage cells, the gp130 modulator, which was named RCGD 423 (regulator of cartilage growth and differentiation), caused increased cell proliferation and reduced the number of dying cells.

The investigators further reported in the February 2018 issue of the journal Annals of Rheumatic Diseases that in a rat partial meniscectomy model, RCGD 423 greatly reduced chondrocyte hypertrophy, loss, and degeneration while increasing chondrocyte proliferation beyond that observed in response to injury. Moreover, RCGD 423 improved cartilage healing in a rat full-thickness osteochondral defect model, increasing proliferation of mesenchymal cells in the defect and also inhibiting breakdown of cartilage matrix in de novo generated cartilage.

"The goal is to make an injectable therapy for an early to moderate level of arthritis," said senior author Dr. Denis Evseenko, associate professor of orthopedic surgery at the University of Southern California. "It is not going to cure arthritis, but it will delay the progression of arthritis to the damaging stages when patients need joint replacements, which account for a million surgeries a year in the United States."

Related Links:
University of Southern California


New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Portable Electronic Pipette
Mini 96
New
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
New
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: AiPlex VAS for the MosaiQ platform is designed to help reduce time-to-diagnosis for patients with autoimmune vasculitis (Photo courtesy of AliveDx)

Novel Multiplex Assay Supports Diagnosis of Autoimmune Vasculitis

Autoimmune vasculitis and related conditions are difficult to diagnose quickly and accurately, often requiring multiple tests to confirm the presence of specific autoantibodies. Traditional methods can... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.